New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
27. Oktober 2020 06:56 ET
|
Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
DPW Holdings’ Announces that the Journal of Alzheimer’s Disease Highlights Milestone Research (AL002) Licensed by Alzamend Neuro® from the University of South Florida
27. Oktober 2020 06:30 ET
|
Alzamend Neuro, Inc.
NEWPORT BEACH, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) announced that the Journal of Alzheimer’s...